hepatitis C virus

New antibody targets hepatitis C virus

harminka — Thu, 06 Aug 2009 11:24:01 -0500

Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus.

New antibody prevents infection by hepatitis C virus

harminka — Tue, 05 May 2009 11:47:47 -0500

Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV). The new antibody effectively neutralized the Hepatitis C virus in culture, and then prevented infection by the virus in a pre-clinical animal model of the disease.

Hepatitis C virus increases risk of developing liver cancer

harminka — Tue, 23 Dec 2008 12:12:49 -0600

Hepatitis C virus (HCV) causes hepatitis and increased risk of developing liver cancer. Current treatments are expensive, have severe side effects, and fail in about half the patients treated

Investigational genotype 1 hepatitis C treatment

harminka — Mon, 03 Nov 2008 10:02:23 -0600

New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.

Risk factors of idiopathic pulmonary fibrosis in HCV patients

harminka — Thu, 23 Oct 2008 12:13:14 -0500

Hepatitis C virus (HCV) is one of the more common causes of chronic liver disease in world with a variety of extrahepatic complications such as essential mixed cryoglobulinemia, membranoproliferative glomerulonep hritis, autoimmune thyroiditis, sialadenitis, and cardiomyopathy.

New treatment therapy helps inhibit hepatitis C

harminka — Fri, 01 Aug 2008 15:15:47 -0500

Two new studies examine the use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C. The reports appear in the August issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

Improved culture system for hepatitis C virus infection

harminka — Wed, 16 Jul 2008 01:20:23 -0500

A University of California, San Diego School of Medicine researcher has developed the first tissue culture of normal, human liver cells that can model infection with the Hepatitis C virus (HCV) and provide a realistic environment to evaluate possible treatments.

How to increase chances of remaining virus free Pakistani patients with HCV?

harminka — Wed, 21 May 2008 10:37:21 -0500

Hepatitis C is a health care problem all over the world, with 130 million patients infected the world over. The treatment is expensive and has variable results according to the genotype of the infecting virus. The first land mark in treatment is the virus clearance at the end of the treatment called End Treatment Response (ETR), but many of the patients achieving the ETR have a relapse within the next six months

Scientists develop a process to disrupt hepatitis C virion production

harminka — Fri, 21 Mar 2008 14:29:28 -0500

HCV is a significant human pathogen, infecting more than three percent of the world’s population. The incidence of infection in the United States has been estimated to be as high as 4 million cases.

Scientists see Norwalk virus' Achilles heel

harminka — Wed, 19 Mar 2008 08:52:37 -0500

Using the Canadian Light Source synchrotron, an international team led by University of Calgary researcher Ken Ng has determined the detailed structure of the enzyme the Norwalk virus uses to make copies of its genetic code in order to replicate itself. The information is crucial to developing drugs that could be used to treat outbreaks of Norwalk and other related viruses.

Nearly 40,000 Endoscopy Center of Southern Nevada Patients Asked Hepatitis C Testing

Armen Hareyan — Thu, 28 Feb 2008 19:07:34 -0600

Nevada Health District notifies patients of potential exposure of Endoscopy Center of Southern Nevada patients to hepatitis C and urges testing for approximately 40,000 patients.

Grapefruit compound may help combat hepatitis C infection

harminka — Tue, 05 Feb 2008 10:29:30 -0600

A compound that naturally occurs in grapefruit and other citrus fruits may be able to block the secretion of hepatitis C virus (HCV) from infected cells, a process required to maintain chronic infection.